Sartorius Reports Strong Nine-Month Performance

In the first nine months of 2026, Sartorius reported solid growth across both its Lab Products & Services and Bioprocess Solutions divisions. The life science company achieved an 8.1% increase in operational sales revenue in constant currencies, excluding U.S. tariff compensations. Underlying EBITDA margin rose slightly to 30.2%.

The Lab Products & Services division saw significant gains, driven by increased demand for bioanalytics. The division's sales reached €524 million, with recurring consumables being a major growth contributor. Meanwhile, the Bioprocess Solutions division continued its upward trajectory, with sales revenue hitting €2,213 million, supported by new product introductions.

All global regions contributed to the growth, with the Asia/Pacific region standing out with an 11% increase. The company has refined its full-year guidance, with the Lab division expected to be at the upper end of growth expectations.